drugset / Trial / NCT01492725

Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial

NCT01492725

Phase 2 Terminated 70 enrolled Neuroscience Trials Australia
RandomizedParallel-groupOpen-labelTreatment

Summary

Patients presenting to the emergency department with acute ischaemic stroke, who are eligible for standard intravenous tPA therapy within 4.5 hours of stroke onset will be assessed for "dual target" major vessel occlusion and mismatch to determine their eligibility for randomisation into the trial. If the patient gives informed consent they will be randomised 50:50 using central computerised allocation to intra-arterial clot retrieval after IV tPA or IV tPA alone. The trial is prospective, randomised, open-label, blinded endpoint (PROBE) design.

Timeline

Start
2012-06
Primary completion
2014-12
Completion
2014-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alteplase Protein / enzyme biologic 0.9 mg/kg Intravenous

Indications